GoldenGolden
Advanced Search
Northpond Ventures

Northpond Ventures

A Maryland based venture capital firm founded in 2018 by Michael P. Rubin and Sharon that invests in life sciences, technology, and affiliated industries.

Northpond Ventures is a Bethesda, Maryland based venture capital firm founded in 2018 by Michael P. Rubin and Sharon Kedar.

The firm prefers to invest in artificial intelligence, machine learning, diagnostics, life science, biology and therapeutics sectors. The firm invests in venture rounds.

The notable investment portfolio of Northpond Ventures includes Inflammatix, IsoPlexis, SGIDNA, Chroma Code, Intabio, General Automation Lab Technologies, Vizgen, SeLuxDiagnostics.

As of January 2020, North pond Ventures has made 23 investments.

Timeline

2008
Founded

Funding Rounds Participated In

Invested in

People

Name
Role
LinkedIn

Jesse Dill

Venture Professional

Pat Smerkers

Director of Finance and Operations

Paxton Major

Venture Professional

Andrew Lee

Venture Professional

Andrew Lee

Venture Professional

Connor McDermott

Venture Professional

David Mann

Executive Office Administrator

Mark Mitchell

Controller

Meredith Kohls

Office Coordinator

Michael Rubin

Founder and CEO

Samantha Shalom

Venture Professional

Shaan Gandhi

Principal

Sharon Kedar

Co-Founder, Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

ChromaCode

General Automation Lab Technologies

Inflammatix

Intabio

IsoPlexis

SeLux Diagnostics

SGI DNA

Vizgen

News

Title
Author
Date
Publisher
Description
Conor Hale
September 28, 2021
FierceBiotech
One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself--be it RNA, DNA or CRISPR proteins. Kytopen aims to provide a fast and scalable method.
FinSMEs
September 28, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
FinSMEs
September 24, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Hawthorne Effect
June 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Hawthorne EffectTM, a solution for decentralizing clinical trials, today announced the successful closing of a $20 million Series A round of...
Outcomes4Me Inc.
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- Outcomes4Me Inc., Entwickler einer durch künstliche Intelligenz (KI) gestützten Plattform, die Krebspatienten bei der Navigation durch ihre...
Outcomes4Me Inc.
April 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- Outcomes4Me Inc., développeur d'une plateforme alimentée par l'intelligence artificielle (IA) pour permettre aux patients atteints de cancer de...
FinSMEs
April 23, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Andrea Park
April 23, 2021
FierceBiotech
Still riding the wave of its massive growth in 2020, Current Health has closed an overstuffed funding round in support of its remote care management platform.
Heather Landi
April 22, 2021
FierceHealthcare
With the accelerated shift to healthcare at home, enterprise remote care management platform Current Health has seen tremendous growth during the pandemic. The company pulled in $43 million in series B financing from top healthcare and pharmaceutical venture capital investors.
Mark Terry
March 16, 2021
BioSpace
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today's are that large, there is still plenty of money on the move. Here's a look.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.